May 31st 2024
This study quantified the trends over time in utilization of, spending on, and access to CT fractional flow reserve, the first artificial intelligence (AI)–enabled clinical software reimbursed by Medicare.
Dr Michael Diaz on the Importance of Site of Care, PBM Reform
March 17th 2022Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, speaks on takeaways from his discussions on site of care and pharmacy benefit managers (PBMs) at the 2022 Community Oncology Conference.
Watch
Impact of Payment Models on Medical Specialist Physician Practice Patterns
This article explores the impact of payment models (fee for service vs salary based) on practice patterns, including wait times and care for patients with chronic diseases.
Read More
Report: Economic Burden of Rare Diseases Is 10 Times Higher Than Mass Market Diseases
March 2nd 2022The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment is available.
Read More
Dana-Farber’s Sands: More Lung Screening Would Have Greatest Impact on Cancer Mortality
February 22nd 2022Jacob Sands, MD, who leads the small cell lung cancer research program at Dana-Farber Cancer Institute, speaks with The American Journal of Managed Care (AJMC®) about the need for more patients who meet the criteria for lung screening to catch cancer before it reaches an advanced stage.
Read More
Contributor: 3 Ways Health Plans Can Ensure Risk Adjustment Compliance
February 15th 2022By making diligent compliance efforts a priority in the years ahead, health plans can shore up existing processes to achieve financial success and ensure risk adjustment as regulatory bodies take aim at organizational missteps.
Read More
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of axi-cel as second-line therapy in relapsed or refractory large B-cell lymphoma. A target action date is set for April 1, 2022.
Read More
Developing Strategies to Drive Value in Mental Health Care, Part 4
February 14th 2022Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
Read More
Developing Strategies to Drive Value in Mental Health Care, Part 3
February 14th 2022Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
Read More
Developing Strategies to Drive Value in Mental Health Care, Part 2
February 14th 2022Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
Read More
Developing Strategies to Drive Value in Mental Health Care, Part 1
February 14th 2022Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
Read More
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds
February 8th 2022Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Read More